Zobrazeno 1 - 7 of 7 pro vyhledávání: '"D. H. Berdeaux"'
1
A phase 1 study of daily oral perifosine (P) and weekly gemcitabine (G)
Autor: L. Gardner, D. H. Berdeaux, R. Birch, B. Ebrahimi, J. P. Allerton, I. C. Henderson, M. Diaz-Lacayo, J. J. Nemunaitis, S. Weiss
Publikováno v: Journal of Clinical Oncology. 24:13084-13084
13084 Background: Miltefosine (M) has been shown to be synergistic with gemcitabine (G) in vitro (Georgieva Cancer Letters 182: 163–174, 2002). Perifosine (P) is a derivative of M with less GI toxicity. Methods: Twenty-two patients (pts) were enrol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::886b4302c54a51ab6b5a370a13ee0a4b
https://doi.org/10.1200/jco.2006.24.18_suppl.13084
Zobrazit plný text záznamu
2
A phase 1 study of daily oral perifosine (P) with every 3-week paclitaxel (T)
Autor: M. A. Rettenmaier, D. H. Berdeaux, I. C. Henderson, M. Diaz-Lacayo, R. Birch, R. Shiffman, T. F. Goggins, John Nemunaitis
Publikováno v: Journal of Clinical Oncology. 24:13134-13134
13134 Background: Perifosine is a novel alkylphospholipid that has been shown to affect multiple signal transduction pathways including Akt, MAPK and JNK (Kondapaka, Mol. Canc. Ther 2: 1093–1103. 2003). Treatment with a taxane initially activates A
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::288afadf39225f2834cbb70e0d2bb98b
https://doi.org/10.1200/jco.2006.24.18_suppl.13134
Zobrazit plný text záznamu
4
Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease
Autor: F L, Meyskens, D H, Berdeaux, B, Parks, T, Tong, L, Loescher, T E, Moon
Publikováno v: Cancer. 62(6)
The authors have studied the natural history of 377 patients with Stage I cutaneous malignant melanoma followed at the Arizona Cancer Center, Tucson. Two hundred eight patients, or 55%, remained free of metastatic disease after a median follow-up of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6b0bbe848832039de00c34d12bb3291f
https://pubmed.ncbi.nlm.nih.gov/3409189
Zobrazit plný text záznamu
5
Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease
Autor: D H, Berdeaux, F L, Meyskens, B, Parks, T, Tong, L, Loescher, T E, Moon
Publikováno v: Cancer. 63(7)
The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage II
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6de05d3ec00d7c8da6fdc00f48371b90
https://pubmed.ncbi.nlm.nih.gov/2920369
Zobrazit plný text záznamu
6
Clinical-biologic patterns of metastatic melanoma and their effect on treatment
Autor: D H, Berdeaux, T E, Moon, F L, Meyskens
Publikováno v: Cancer treatment reports. 69(4)
We have identified three distinct groups of patients with metastatic malignant melanoma that differ in their clinical behavior and responsiveness to therapy. These include a favorable group of patients with lymph node or skin metastases, an intermedi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c0c7b26ce9916b1f02ced6d7b38b0d62
https://pubmed.ncbi.nlm.nih.gov/3995510
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje